News Column

Reports from Mayo Clinic Provide New Insights into Age-Related Macular Degeneration

March 3, 2014



By a News Reporter-Staff News Editor at Pain & Central Nervous System Week -- A new study on Age-Related Macular Degeneration is now available. According to news reporting originating from Rochester, Minnesota, by NewsRx correspondents, research stated, "To describe clinical and imaging features of eyes with and without vitreomacular interface disease (VMID) treated with intravitreal anti-vascular endothelial growth factor injections for exudative age-related macular degeneration, followed over an average of 2.5 years. Retrospective interventional case series involving 32 eyes with VMID and 146 eyes without traction."

Our news editors obtained a quote from the research from Mayo Clinic, "Best-corrected visual acuity (BCVA), manually measured central foveal thickness from optical coherence tomography imaging, and the number and timing of intravitreal anti-vascular endothelial growth factor injections were reviewed. Eyes with VMID and exudative age-related macular degeneration received more intravitreal injections (mean 14.7) for 4 years than eyes without traction (mean 9.5) (P = 0.0224). Eyes with VMID had similar BCVA to eyes without traction at baseline (P = 0.8013) and Year 1 through Year 4 (P = 0.5417, 0.6275, 0.4574, 0.0570, respectively). Best BCVA showed significant improvement over baseline BCVA in eyes with (logarithm of the minimum angle of resolution 0.67-0.47, P = 0.0182) and without (logarithm of the minimum angle of resolution 0.61-0.44, P = 0.0001) VMID. Central foveal thickness was similar to eyes without traction at baseline and Year 1 through Year 3 and declined over time in eyes with VMID. In eyes with VMID, anti-vascular endothelial growth factor therapy resulted in improved BCVA and decreased central foveal thickness despite continued vitreomacular traction."

According to the news editors, the research concluded: "Eyes with VMID required more intravitreal anti-vascular endothelial growth factor agents than eyes without VMID."

For more information on this research see: VISUAL AND ANATOMICAL OUTCOMES OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION AND VITREOMACULAR INTERFACE DISEASE Vitreomacular Adhesion and Epiretinal Membrane. Retina-The Journal of Retinal and Vitreous Diseases, 2013;33(7):1359-1364. Retina-The Journal of Retinal and Vitreous Diseases can be contacted at: Lippincott Williams & Wilkins, 530 Walnut St, Philadelphia, PA 19106-3621, USA (see also Age-Related Macular Degeneration).

The news editors report that additional information may be obtained by contacting A.E. Green-Simms, Mayo Clinic, Dept. of Ophthalmol, Rochester, MN 55905, United States. Additional authors for this research include B.M. Fechtel, Z. Agarwal and S.J. Bakri.

Keywords for this news article include: Therapy, Rochester, Minnesota, Eye Diseases, United States, Retinal Diseases, Epiretinal Membrane, Retinal Degeneration, North and Central America, Endothelial Growth Factors, Age-Related Macular Degeneration, Intercellular Signaling Peptides and Proteins

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Pain & Central Nervous System Week


Story Tools